Infos und quasi Blog

Phytocannabinoids as anti-inflammatory agents: Synergistic effects when combined with Cannabis sativa L. matrices Source / Quelle: https://www.sciencedirect.com/science/article/pii/S0378874125018276?via%3Dihub Abstract Ethnopharmacological relevance Cannabis sativa L. has a long history of traditional use for the treatment of pain and inflammatory disorders in both Asian and European medical systems, which supports its investigation as a source of bioactive compounds with potential relevance for chronic immune-mediated diseases. Aim of the study This study evaluated the ten major non-psychotropic phytocannabinoids for their anti-inflammatory and antioxidant activities, and for synergistic interactions with non-cannabinoid matrices derived from the same plant (polar, non-polar and terpenoid). Material and methods Anti-inflammatory effects were assessed in macrophage-differentiated THP-1 cells by measuring pro-inflammatory cytokine production (ELISA) and nuclear factor kappa B (NF-κB) pa

Marijuana Use for Symptom Control in Inflammatory Bowel Disease: Patients’ Perceptions and Patterns of Use Source / Quelle: https://karger.com/mca/article/9/1/211/951948/Marijuana-Use-for-Symptom-Control-in-Inflammatory Abstract Introduction: Many patients with inflammatory bowel disease (IBD) use marijuana for disease-related symptoms. Data regarding reasons for usage, impact, and perceptions on its effects is lacking. Our study aimed to understand patterns of marijuana use, underlying symptom response, and beliefs about marijuana in patients with IBD. Methods: An anonymous REDCap survey comprised of 39 questions on demographics, disease features, patterns of marijuana use, symptoms, quality of life, and true/false statements about marijuana was administered to 108 participants recruited from University of Florida (UF) IBD clinic. Results: Participants were 47.2% male and 51.9% female. While a significant percentage of subjects reported co-morbid depression/anxiety (61.1%), the percen

Neurobiological and Molecular Mechanisms of Cannabidiol in Depressive Disorders: A Preclinical Systematic Review Source / Quelle: https://prmjournal.emnuvens.com.br/revista/article/view/944 Abstract Purpose: This review aims evaluated preclinical studies published in the last five years investi gating the antidepressant-like effects of CBD and related cannabinoids. Methods: This work is a systematic review. The entire process of selecting and choosing the studies for the review was carried out according to the PRISMA protocol. The descriptors used were "Depressive Disorder", "Cannabidiol", and "Phytotherapy". Seven experimental studies met the inclusion criteria. Results: The reviewed evidence demonstrates that CBD reduces immobility in the forced swim test, increases sucrose preference, and modulates molecular pathways associated with neuroplasticity and inflammation. Key mechanisms include activation of AMPA receptors, modulation of serotonergic and noradrenergic transmission, reduct

The role of cannabidiol treatment in reducing HER2 expression and inducing ER stress-mediated apoptosis in HER2-positive breast cancer Source / Quelle: https://link.springer.com/article/10.1186/s12906-026-05523-y Abstract Background Cannabidiol (CBD) has attracted attention as a potential anticancer agent due to its observed efficacy, particularly in breast cancer. However, the exact molecular pathway through which it exerts its anticancer effects remains unknown. The present study aimed to investigate the effects of CBD on the HER2 receptor, endoplasmic reticulum (ER) stress signaling pathway, and apoptosis in HER2-positive breast cancer cells, as well as to examine the effect of trastuzumab (TZB), used in treatment, on the ER stress signaling pathway. Methods For this purpose, SKBR3 cells were treated with CBD at three different concentrations (9.38, 18.75, and 37.5 µM), TZB at 62.5 µg/mL, and two combinations of TZB and CBD (18.75 µM CBD + 62.5 µg/mL TZB and 37.5 µM CBD + 62.5 µg/mL

Efficacy of cannabinoids for insomnia and sleep disturbance: A systematic review and meta-analysis of randomized controlled trials Source / Quelle: https://www.sciencedirect.com/science/article/abs/pii/S1389945726004326 Abstract Background Insomnia is a common sleep disorder that presents with difficulty falling asleep or staying asleep. Standard hypnotics often lead to tolerance and dependency, prompting interest in cannabinoids as alternative sleep aids. This study evaluated the efficacy and safety of cannabinoids in improving sleep among adults with insomnia or poor sleep quality. Methods PubMed, EMBASE, Cochrane Library, Scopus, and Web of Science were searched from inception to January 2025 for randomized controlled trials (RCTs) comparing cannabinoids with placebo or melatonin. Primary outcomes were changes in Insomnia Severity Index (ISI) and Pittsburgh Sleep Quality Index (PSQI). Pooled mean differences (MD) or risk ratios (RR) with 95% confidence intervals (CI) were calculated

Source / Quelle: https://www.ncbi.nlm.nih.gov/books/NBK501587/ Summary of Use during Lactation The main psychoactive component of cannabis, tetrahydrocannabinol (THC), is excreted into breastmilk in small quantities. The duration of detection of THC in milk has ranged from 6 days to greater than 6 weeks in various studies. Computer modeling studies predicted a half-life in milk of 12 to 39 hours, which is consistent with a THC clearance from milk in 2.5 to 8 days. Concern has been expressed regarding the possible effects of cannabis on neurotransmitters, nervous system development and endocannabinoid-related functions.[1,2] A 1-year study found that daily or near daily use might retard the breastfed infant’s motor development, but not growth or intellectual development.[3] This and other studies[4,5] found that occasional maternal cannabis use during breastfeeding did not have any discernable effects on breastfed infants, but the studies were inadequate to rule out all long-term harm a